Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia th… Read more
Sun Pharma Advanced Research Company Limited (SPARC) - Total Assets
Latest total assets as of September 2025: ₹3.22 Billion INR
Based on the latest financial reports, Sun Pharma Advanced Research Company Limited (SPARC) holds total assets worth ₹3.22 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sun Pharma Advanced Research Company Limited - Total Assets Trend (2007–2025)
This chart illustrates how Sun Pharma Advanced Research Company Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sun Pharma Advanced Research Company Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Sun Pharma Advanced Research Company Limited's total assets of ₹3.22 Billion consist of 7.8% current assets and 92.2% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0.6% |
| Accounts Receivable | ₹160.60 Million | 4.8% |
| Inventory | ₹19.54 Million | 0.6% |
| Property, Plant & Equipment | ₹992.55 Million | 29.6% |
| Intangible Assets | ₹536.50 Million | 16.0% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Sun Pharma Advanced Research Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sun Pharma Advanced Research Company Limited's current assets represent 7.8% of total assets in 2025, a decrease from 45.8% in 2007.
- Cash Position: Cash and equivalents constituted 0.6% of total assets in 2025, up from 0.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is property, plant & equipment at 29.6% of total assets.
Sun Pharma Advanced Research Company Limited Competitors by Total Assets
Key competitors of Sun Pharma Advanced Research Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Sun Pharma Advanced Research Company Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Sun Pharma Advanced Research Company Limited generates 0.21x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Sun Pharma Advanced Research Company Limited is currently not profitable relative to its asset base.
Sun Pharma Advanced Research Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.03 | 0.32 | 0.28 |
| Quick Ratio | 0.03 | 0.32 | 0.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹-4.77 Billion | ₹ -1.88 Billion | ₹ -1.74 Billion |
Sun Pharma Advanced Research Company Limited - Advanced Valuation Insights
This section examines the relationship between Sun Pharma Advanced Research Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 56.32 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -34.9% |
| Total Assets | ₹3.36 Billion |
| Market Capitalization | $121.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sun Pharma Advanced Research Company Limited's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sun Pharma Advanced Research Company Limited's assets decreased by 34.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sun Pharma Advanced Research Company Limited (2007–2025)
The table below shows the annual total assets of Sun Pharma Advanced Research Company Limited from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹3.36 Billion | -34.85% |
| 2024-03-31 | ₹5.15 Billion | -37.96% |
| 2023-03-31 | ₹8.30 Billion | +196.38% |
| 2022-03-31 | ₹2.80 Billion | +21.94% |
| 2021-03-31 | ₹2.30 Billion | -15.73% |
| 2020-03-31 | ₹2.73 Billion | -31.60% |
| 2019-03-31 | ₹3.98 Billion | +29.04% |
| 2018-03-31 | ₹3.09 Billion | +12.69% |
| 2017-03-31 | ₹2.74 Billion | +68.47% |
| 2016-03-31 | ₹1.63 Billion | +14.01% |
| 2015-03-31 | ₹1.43 Billion | -22.27% |
| 2014-03-31 | ₹1.84 Billion | -12.18% |
| 2013-03-31 | ₹2.09 Billion | +144.08% |
| 2012-03-31 | ₹856.26 Million | +10.49% |
| 2011-03-31 | ₹774.98 Million | +7.28% |
| 2010-03-31 | ₹722.39 Million | +17.36% |
| 2009-03-31 | ₹615.53 Million | +0.07% |
| 2008-03-31 | ₹615.09 Million | +11.31% |
| 2007-03-31 | ₹552.58 Million | -- |